Entheon Biomedical Corp. (FRA:1XU)
Germany · Delayed Price · Currency is EUR | Market Cap | 486.67K -36.2% |
| Revenue (ttm) | n/a |
| Net Income | 26.93K |
| EPS | 0.00 |
| Shares Out | n/a |
| PE Ratio | 15.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 0.0300 |
| Previous Close | 0.0300 |
| Day's Range | 0.0300 - 0.0300 |
| 52-Week Range | 0.0150 - 0.0670 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 25, 2027 |
About Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada. [Read more]
News
Entheon Adopts Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that it has elected to part...
CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") wishes to correct the effective date of the...
Entheon Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes to t...
Entheon Announces Termination of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that further to its news release dated January...
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a de...
Entheon Announces Letter of Intent with Nutravisor Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has enter...
Entheon Issues Incentive Stock Options
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted opti...
Entheon Announces Termination of Mentis AI Agreement
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release...
Entheon Announces Agreement to Acquire Mentis AI
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entere...
Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news r...
Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a d...
Entheon Biomedical Announces Non-Brokered Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the resear...
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform
Improved Genetic Screening Platform to Strengthen Entheon's Psychedelic-Assisted ProtocolsVancouver, British Columbia--(Newsfile Corp. - March 29, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ...
Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the resea...
Entheon Biomedical Announces EBIQ-101 First-Patient Dose
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the re...
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a company focused on the research and ...
Entheon Biomedical Announces the Approval of DMT Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the res...
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today
Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (F...
Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the rese...
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel
Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuascaVancouver, British Columbia--(Newsfile Cor...
Entheon Biomedical Announces EEG Patent Application & Provides Research Update
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the re...
Entheon to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the res...
Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the res...
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays UnderwayVancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Entheon Biomedical Corp. (CSE: ...
BTV Investor Alert Video: Entheon Biomedical Corp. - Treating Addiction
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) - Researching and developing DMT, one of the most powerful psychedelics in existence, to addres...